Engineered immune cells take on rare sarcomas in early trial
NCT ID NCT07467122
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing a new treatment for people with advanced mesenchymal malignancies (a group of rare cancers including sarcomas). The treatment uses the patient's own immune T cells, which are modified in a lab to recognize and attack cancer cells that carry a protein called MAGE-A4. The study will enroll 15 participants to primarily check safety and see if the tumors shrink.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TCR-T cells targeting MAGE-A4
- What this could lead to
- If it works, this could point toward a new treatment option for advanced mesenchymal cancers that have not responded to standard therapies.
- What could go wrong
- This is a very early Phase 1 trial with only 15 participants, so it is too small to prove effectiveness. There are also risks of serious side effects like cytokine release syndrome or neurotoxicity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MESENCHYMAL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen Memorial Hospital
RECRUITINGGuangzhou, Guangdong, 510120, China